Conjugated estrogens/bazedoxifene


Conjugated estrogens/bazedoxifene

Drug updated on 4/24/2024

Dosage FormTablet (oral; 0.45 mg conjugated estrogens and 20 mg bazedoxifene)
Drug ClassConjugated estrogens with an estrogen agonist/antagonist
Ongoing and
Completed Studies


  • Indicated in women with a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause.
  • Indicated in women with a uterus for the prevention of postmenopausal osteoporosis.

Latest News

loading GIF

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Conjugated estrogens/bazedoxifene (Duavee) is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis in women with a uterus.
  • Three studies were reviewed, comparing Duavee's safety and effectiveness against other treatments for menopausal symptoms, specifically vasomotor symptoms and preventing postmenopausal osteoporosis.
  • The first study suggests that Duavee has comparable efficacy to fezolinetant (a non-hormonal therapy) in reducing the frequency of vasomotor symptoms (VMS). It also indicates potential superior efficacy over other non-hormone therapies such as paroxetine, desvenlafaxine, and gabapentin.
  • According to the second study, conjugated estrogens/bazedoxifene shows significant improvements in hot flushes, sleep disturbance, and menopause-related quality of life compared with placebo. A dose combination BZA 20mg/CE 0.625mg performs better than BZA 20mg/CE 0.45mg.
  • The third study reveals that bazedoxifene-conjugated estrogens have a therapeutic effect on sleep disturbances associated with vasomotor symptoms offering superior benefits over placebo/control. It displays comparable benefits to oral combined hormone therapy for managing these disturbances according to network meta-analysis results.
  • While specific information on adverse event-related discontinuation rates due to Duavee was not directly provided from the studies reviewed, certain medications including eszopiclone and oral combined hormone therapy were linked with higher adverse event-related discontinuation rates. This information is vital for evaluating tolerability and safety considerations.